- Schellekens H. Biosimilar therapeutics: What do we need to consider? NDT Plus. 2009;2(Suppl 1):i27–i36.
- Gleason P. RA drug therapy projected to exceed $50k per person in 2022. Prime Therapeutics. 2013 May 23.
Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.
The Foundation is the largest private funding source for rheumatology research and training in the U.S.
Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.